Equities analysts forecast that Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) will announce ($0.17) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Keryx Biopharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.19). Keryx Biopharmaceuticals reported earnings per share of ($0.39) in the same quarter last year, which would indicate a positive year-over-year growth rate of 56.4%. The business is scheduled to announce its next earnings results on Wednesday, November 8th.

According to Zacks, analysts expect that Keryx Biopharmaceuticals will report full-year earnings of ($1.29) per share for the current fiscal year, with EPS estimates ranging from ($1.32) to ($1.25). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.32) per share, with EPS estimates ranging from ($0.39) to ($0.25). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that follow Keryx Biopharmaceuticals.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.60). Keryx Biopharmaceuticals had a negative return on equity of 2,902.87% and a negative net margin of 431.89%. The business had revenue of $15.10 million during the quarter, compared to analysts’ expectations of $14.51 million. During the same period in the prior year, the firm posted ($0.42) EPS. The firm’s revenue for the quarter was up 62.4% on a year-over-year basis.

KERX has been the topic of several recent analyst reports. Cowen and Company reiterated a “hold” rating on shares of Keryx Biopharmaceuticals in a research note on Saturday, June 17th. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price on the stock in a research note on Wednesday, July 12th. BidaskClub downgraded Keryx Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Maxim Group reiterated a “buy” rating and set a $9.00 target price on shares of Keryx Biopharmaceuticals in a research note on Thursday, July 20th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $7.00 target price (up from $4.00) on shares of Keryx Biopharmaceuticals in a research note on Tuesday, July 25th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $7.48.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/08/zacks-analysts-expect-keryx-biopharmaceuticals-inc-kerx-will-announce-earnings-of-0-17-per-share.html.

Keryx Biopharmaceuticals (KERX) traded up 5.15% on Friday, reaching $7.56. The company’s stock had a trading volume of 3,040,542 shares. Keryx Biopharmaceuticals has a 12-month low of $4.11 and a 12-month high of $8.38. The company’s 50 day moving average price is $7.15 and its 200-day moving average price is $6.68. The stock’s market cap is $897.75 million.

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Keryx Biopharmaceuticals by 5.1% in the 2nd quarter. Vanguard Group Inc. now owns 7,198,269 shares of the biopharmaceutical company’s stock worth $52,043,000 after buying an additional 349,521 shares during the last quarter. State Street Corp boosted its stake in shares of Keryx Biopharmaceuticals by 20.1% in the 1st quarter. State Street Corp now owns 3,479,370 shares of the biopharmaceutical company’s stock worth $21,432,000 after buying an additional 582,624 shares during the last quarter. Rice Hall James & Associates LLC boosted its stake in shares of Keryx Biopharmaceuticals by 24.3% in the 2nd quarter. Rice Hall James & Associates LLC now owns 1,666,934 shares of the biopharmaceutical company’s stock worth $12,052,000 after buying an additional 326,285 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Keryx Biopharmaceuticals by 6.9% in the 2nd quarter. Northern Trust Corp now owns 1,089,860 shares of the biopharmaceutical company’s stock worth $7,881,000 after buying an additional 70,420 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Keryx Biopharmaceuticals by 3.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 963,054 shares of the biopharmaceutical company’s stock worth $6,963,000 after buying an additional 32,687 shares during the last quarter. Hedge funds and other institutional investors own 65.19% of the company’s stock.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Get a free copy of the Zacks research report on Keryx Biopharmaceuticals (KERX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related stocks with our FREE daily email newsletter.